ABO 1009 DP
Alternative Names: ABO 1009-DP; COVID-19 mRNA vaccine - Suzhou Abogen Biosciencea; COVID-19-Omicron-mRNA-Vaccine - Suzhou Abogen Biosciences; SARS-CoV-2 mRNA vaccine - Suzhou Abogen BiosciencesLatest Information Update: 05 Sep 2022
At a glance
- Originator Suzhou Abogen Biosciences
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 22 Aug 2022 Phase-I clinical trials in COVID-2019 infections (Prevention) in United Arab Emirates (IM) (NCT05433194)
- 08 Jul 2022 Phase-I clinical trials in COVID-2019 infections (Prevention) in Indonesia (IM) (NCT05434585)
- 04 Jul 2022 Suzhou Abogen Biosciences plans a phase I/II trial in COVID-2019 infections (Prevention, In volunteers) in China (IM,Injection) in June 2022 (NCT05433194)